Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis
Open Access
- 8 April 2024
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 24 (5) , 411-420
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Beretta
This publication has 56 references indexed in Scilit:
- 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingESMO Open, 2024
- Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)Cancer Treatment Reviews, 2023
- The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancerCancer Treatment Reviews, 2022
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancerEuropean Journal of Cancer, 2022
- Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and VomitingDrugs, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trialAnnals of Oncology, 2020
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1European Journal of Cancer, 2019
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloadsInvestigational New Drugs, 2017
- Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational surveySupportive Care in Cancer, 2015